Securities and Exchange Commission. Double asterisks denote omissions. COLLABORATION AND OPTION AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND ABBVIE BIOTECHNOLOGY LTDCollaboration and Option Agreement • March 14th, 2018 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This COLLABORATION AND OPTION AGREEMENT (this “Agreement”) is entered into and made effective as of February 16, 2018 (the “Effective Date”), by and between Voyager Therapeutics, Inc., a Delaware corporation, having its principal place of business at 75 Sidney Street, Cambridge, MA 02139 (“Voyager”), and AbbVie Biotechnology Ltd, a corporation organized under the laws of Bermuda having its principal place of business at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda (“AbbVie”). Voyager and AbbVie shall be referred to herein individually as a “Party” and collectively as the “Parties”.
